Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAR-T cell therapy embarks on autoimmune disease

8 Oct 2024

Abstract excerpt

Chimeric antigen receptor T cell therapy targeting the B-cell antigen CD19 (CD19CAR-T) has shown remarkable effectiveness against leukaemia/lymphoma following treatment failure with the B-cell targeting monoclonal antibodies (mAbs) Rituximab and Obinatuzumab in combination with chemotherapy [ 1 , 2 ]. B-cell aplasia is a ubiquitous off-tumour-on-target phenomenon of CD19CAR-T [ 3 ].

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosimilars and Bioanalytical Methods
Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39379698
DOI: 10.1038/s41409-024-02429-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAR-T cell therapy embarks on autoimmune diseasePMID 39379698Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief reviewSemantic proximity Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

TCR activation impairs CAR-T cytotoxicity against separate target cellsSemantic proximity Read ↗

Anti-CD19 CAR-T cell therapy for acquired hemophilia ASemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

Autoimmune disease is the next frontier for CAR T cell therapySemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

CAR-T AND autoimmune diseases in nervous systemSemantic proximity Read ↗

Adapter CAR T Cell Therapy for the Treatment of B-Lineage LymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.